Drug Overview
Gocovri (Adamas Pharmaceuticals) is an extended-release formulation of amantadine, uniquely indicated for the treatment of levodopa-induced dyskinesia (LID) in Parkinson’s disease. While amantadine has been available as an anti-Parkinson drug since 1968, the specific formulation in Gocovri was approved in August 2017 following investigations into the effect of N-methyl-D-aspartate receptor antagon.on dyskinesia. Gocovri is administered once daily at bedtime, allowing for amantadine levels to slowly increase during the night and peak in the early morning, when dyskinesia episodes are most frequent.
Gocovri (Adamas Pharmaceuticals) is an extended-release formulation of amantadine, uniquely indicated for the treatment of levodopa-induced dyskinesia (LID) in Parkinson’s disease. While amantadine has been available as an anti-Parkinson drug since 1968, the specific formulation in Gocovri was approved in August 2017 following investigations into the effect of N-methyl-D-aspartate receptor antagon.on dyskinesia. Gocovri is administered once daily at bedtime, allowing for amantadine levels to slowly increase during the night and peak in the early morning, when dyskinesia episodes are most frequent.
Table of Contents
OVERVIEW
LIST OF FIGURES
LIST OF TABLES
